iX Biopharma Ltd. (SGX: 42C)

Market Cap	22.08M
Revenue (ttm)	5.96M
Net Income (ttm)	-10.79M
Shares Out	883.34M
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	100,000
Open	0.0250
Previous Close	0.0260
Day's Range	0.0250 - 0.0250
52-Week Range	0.0240 - 0.0600
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About iX Biopharma

iX Biopharma Ltd., a specialty pharmaceutical and nutraceutical company, develops, manufactures, and commercializes therapies for the treatment of acute and breakthrough pain, and other health conditions in Singapore, Europe, the United States, China, and Australia. The company operates through Pharmaceutical and Nutraceutical segments. It offers Wafermine, a sublingual ketamine wafer, which has completed phase-2 clinical trial for the treatment of acute moderate to severe pain and complex regional pain syndrome; Xativa, a sublingual cannabidio...

• Industry: Pharmaceutical Preparations
• Founded: 2004
• Employees: 45
• Stock Exchange: Singapore Exchange - Catalist
• Ticker Symbol: 42C

Financial Performance

In 2024, iX Biopharma's revenue was 5.96 million, an increase of 0.78% compared to the previous year's 5.91 million. Losses were -10.79 million, 12.3% more than in 2023.